- Home
- CGAU vs RCUS Comparison
CGAU vs RCUS Comparison
Compare CGAU & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- RCUS
- Stock Information
- Founded
- CGAU 2002
- RCUS 2015
- Country
- CGAU Canada
- RCUS United States
- Employees
- CGAU N/A
- RCUS N/A
- Industry
- CGAU Precious Metals
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- CGAU Basic Materials
- RCUS Health Care
- Exchange
- CGAU Nasdaq
- RCUS Nasdaq
- Market Cap
- CGAU 1.3B
- RCUS 1.2B
- IPO Year
- CGAU N/A
- RCUS 2018
- Fundamental
- Price
- CGAU $5.63
- RCUS $7.05
- Analyst Decision
- CGAU Buy
- RCUS Strong Buy
- Analyst Count
- CGAU 2
- RCUS 10
- Target Price
- CGAU $11.00
- RCUS $29.50
- AVG Volume (30 Days)
- CGAU 1.0M
- RCUS 939.9K
- Earning Date
- CGAU 05-13-2025
- RCUS 05-07-2025
- Dividend Yield
- CGAU 3.21%
- RCUS N/A
- EPS Growth
- CGAU N/A
- RCUS N/A
- EPS
- CGAU 0.35
- RCUS N/A
- Revenue
- CGAU $1,214,503,000.00
- RCUS $258,000,000.00
- Revenue This Year
- CGAU N/A
- RCUS N/A
- Revenue Next Year
- CGAU $2.75
- RCUS $25.77
- P/E Ratio
- CGAU $17.67
- RCUS N/A
- Revenue Growth
- CGAU 10.92
- RCUS 120.51
- 52 Week Low
- CGAU $5.46
- RCUS $7.14
- 52 Week High
- CGAU $7.82
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- CGAU 40.84
- RCUS 23.93
- Support Level
- CGAU $6.13
- RCUS $7.51
- Resistance Level
- CGAU $6.37
- RCUS $7.93
- Average True Range (ATR)
- CGAU 0.21
- RCUS 0.42
- MACD
- CGAU -0.01
- RCUS -0.07
- Stochastic Oscillator
- CGAU 0.00
- RCUS 3.65
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.